The Relationship Between the Residual Renal Function and Osteoporosis Treatment
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Longitudinal renal function changes by osteoporotic treatment
研究概览
简要总结
The relationship between osteoporosis drugs and kidney damage is unclear. In this study, we plan to reveal relationship between osteoporosis drugs and kidney damage.
详细描述
Chronic kidney disease (CKD)- mineral and bone disorder (CKD-MBD) is one of the topic in osteoporosis treatment. As many osteoporotic patients are older, many patients are under the deterioration of the renal function. In addition, several drugs might have the potential for kidney damage. But the relationship between osteoporosis drugs and kidney damage is unclear.
The main objective of this study is to reveal relationship between osteoporosis drugs and kidney damage.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Osteoporosis patients
排除标准
- •eGFR < 15
研究组 & 干预措施
Bisphosphonate
干预措施: Bis, SERM Teriparatide, Denosumab (Drug)
Selective estrogen receptor modulator
干预措施: Bis, SERM Teriparatide, Denosumab (Drug)
Teriparatide
干预措施: Bis, SERM Teriparatide, Denosumab (Drug)
Senosumab
干预措施: Bis, SERM Teriparatide, Denosumab (Drug)
结局指标
主要结局
Longitudinal renal function changes by osteoporotic treatment
时间窗: Up to 120 months
次要结局
未报告次要终点
研究者
Toshihiko Kono
Head of Hospital
Tomidahama Hospital